hENT1 expression is predictive of gemcitabine outcome in pancreatic cancer: A systematic review

Table 2 Characteristics of the identified studies

Ref.	Age median, yr (range)	Sex m/tot n (%)	hENT1 method	Chemotherapy	Radiation dose Gy/(Gy/frac)	Outcome measurement	Quality REMARK
Spratlin et al[9]	58 (51-64)1	11 (52)	IHC	Pall Gem	No	OS	10
Giovannetti et al[10]	65 (22-83)	53 (50)	RT-PCR	Pall Gem Adj Gem	45	OS, DFS, TTP, RR	12
Farrell et al[12]	53/63/652	45 (49)	IHC	Adj Gem	50.4	OS, DFS, Tox	17
Maréchal et al[3]	56 (34-83)	23 (51)	IHC	Adj Gem	40-50.4	OS, DFS, Tox	13
Fujita et al[8]	65 (36-86)	42 (60)	RT-PCR	Adj Gem or Resection only	No	OS, DFS	12
Maréchal et al[1]	NR	129 (53)	IHC	Adj Gem	50.4	OS	15
Kawada et al[2]	- (41-81)	33 (52)	IHC	Neo Gem Adj 5-FU	50/2	DSS	9
Morinaga et al[21]	64 (45-74)	17 (63)	IHC	Adj Gem	No	OS, DFS	12
Murata et al[22]	68 (44-87)	38 (69)	IHC	Neo Gem Adj Gem	45/2	OS, DFS, RR	13
Nakagawa et al[23]	67 (41-83)	52 (48)	IHC	Adj Gem + S1	No	OS, DFS	13

¹95%CI;

²Medians in the different hENT1 expression groups. IHC: Immunohistochemistry; RT-PCR: Reverse transcription polymerase chain reaction; Adj: Adjuvant; Neo: Neoadjuvant; Radio: Radiotherapy; Gem: Gemcitabine; Pall: Palliative; OS: Overall survival; DFS: Disease-free survival; Tox: Toxicity; TTP: Time to progression; DSS: Disease-specific survival; RR: Response rate.